Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacl.2024.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipidology: The time is now for specialty recognition.
J Clin Lipidol
November 2024
Lipid Clinic & Division of Cardiology, University of Louisville School of Medicine, Louisville, Kentucky, USA (Dr Kalra).
The GLOB-cAGE Consortium: A Global Cardiovascular Collaborative Network of Older Adults with Cardiovascular Disease.
Am J Epidemiol
January 2025
Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore.
Background: GLOB-cAGE is a newly established unprecedented consortium that brings together cohorts of older persons with cardiovascular disease worldwide. GLOB-cAGE aims to harmonize non-identifiable data from longitudinal cohorts examining cardiovascular health and cardiovascular disease diagnosis and management in older individuals to perform meta-regression analyses using combined repositories of standardized subject-level data points.
Methods And Design: Studies registered into GLOB-cAGE are population-based longitudinal cohort studies or clinical trials, either ongoing or completed, that involve assessing cardiovascular health as a central objective.
Homozygous Familial Hypercholesterolemia Treatment: New Developments.
Curr Atheroscler Rep
January 2025
Carbohydrate and Lipid Metabolism Research Unit, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Purpose Of Review: Homozygous familial hypercholesterolaemia (HoFH) is characterized by marked elevation of low-density lipoprotein cholesterol (LDLC) and premature atherosclerotic cardiovascular disease. This is a review of novel pharmacological therapies to lower LDLC in patients with HoFH.
Recent Findings: Novel therapies can be broadly divided by whether their efficacy is dependent or independent of residual low-density lipoprotein receptor (LDLR) function.
Hypercholesterolemia and inflammation-Cooperative cardiovascular risk factors.
Eur J Clin Invest
January 2025
Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, Milan, Italy.
Background: Maintaining low concentrations of plasma low-density lipoprotein cholesterol (LDLc) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and delays the age at which mature atherosclerotic plaques develop. This substantially reduces the lifetime risk of atherosclerotic cardiovascular disease (ASCVD) events. In this context, plaque development and vulnerability result not only from lipid accumulation but also from inflammation.
View Article and Find Full Text PDFThe German Lipoprotein Apheresis Registry-Summary of the eleventh annual report.
Atherosclerosis
November 2024
Department of Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.
Article Synopsis
- The German Lipoprotein Apheresis Registry (GLAR) began in 2012 and collected data from 2,301 patients undergoing lipoprotein apheresis (LA) for high cholesterol and lipoprotein(a) levels over 11 years.
- The data showed significant reductions in LDL-C (68.8%) and Lp(a) (72.9%) immediately after LA treatment, with substantial decreases in major coronary events (MACE) over the treatment period, particularly an 85% reduction in patients with high Lp(a) levels.
- Adverse events related to LA were low (around 5%) mainly involving minor issues like puncture problems, with no severe side effects leading to treatment termination.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!